Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung fibrosis in mice.


Journal

Biomaterials
ISSN: 1878-5905
Titre abrégé: Biomaterials
Pays: Netherlands
ID NLM: 8100316

Informations de publication

Date de publication:
05 2019
Historique:
received: 19 09 2018
revised: 12 02 2019
accepted: 14 02 2019
pubmed: 11 3 2019
medline: 7 7 2020
entrez: 11 3 2019
Statut: ppublish

Résumé

Idiopathic pulmonary fibrosis (IPF) is a life-threatening progressive lung disorder with limited therapeutic options. While interleukin-10 (IL-10) is a potent anti-inflammatory and anti-fibrotic cytokine, its utility in treating lung fibrosis has been limited by its short half-life. We describe an innovative hydrogel-based approach to deliver recombinant IL-10 to the lung for the prevention and reversal of pulmonary fibrosis in a mouse model of bleomycin-induced lung injury. Our studies show that a hyaluronan and heparin-based hydrogel system locally delivers IL-10 by capitalizing on the ability of heparin to reversibly bind IL-10 without bleeding or other complications. This formulation is significantly more effective than soluble IL-10 for both preventing and reducing collagen deposition in the lung parenchyma after 7 days of intratracheal administration. The anti-fibrotic effect of IL-10 in this system is dependent on suppression of TGF-β driven collagen production by lung fibroblasts and myofibroblasts. We conclude that hydrogel-based delivery of IL-10 to the lung is a promising therapy for fibrotic lung disorders.

Identifiants

pubmed: 30852423
pii: S0142-9612(19)30108-5
doi: 10.1016/j.biomaterials.2019.02.017
pmc: PMC6430662
mid: NIHMS1523478
pii:
doi:

Substances chimiques

Hydrogels 0
Bleomycin 11056-06-7
Interleukin-10 130068-27-8
Hyaluronic Acid 9004-61-9

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

52-62

Subventions

Organisme : NIAID NIH HHS
ID : T32 AI007290
Pays : United States
Organisme : NHLBI NIH HHS
ID : R03 HL133423
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL139664
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM111808
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL134776
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

J Clin Invest. 1994 Dec;94(6):2489-92
pubmed: 7989607
F1000Prime Rep. 2014 Mar 03;6:16
pubmed: 24669297
ACS Appl Mater Interfaces. 2017 Jun 7;9(22):18440-18449
pubmed: 28513136
Am J Physiol Renal Physiol. 2016 Aug 1;311(2):F362-72
pubmed: 26962109
Adv Wound Care (New Rochelle). 2014 Apr 1;3(4):344-355
pubmed: 24757589
J Thorac Cardiovasc Surg. 2008 Nov;136(5):1250-6
pubmed: 19026811
Acta Biomater. 2014 Apr;10(4):1581-7
pubmed: 24021232
J Control Release. 2000 Apr 3;65(3):389-402
pubmed: 10699297
Int J Exp Pathol. 2002 Jun;83(3):111-9
pubmed: 12383190
J Clin Pathol. 1988 Apr;41(4):467-70
pubmed: 3366935
Acta Pharmacol Sin. 2017 Jun;38(6):782-797
pubmed: 28504252
Annu Rev Immunol. 1993;11:165-90
pubmed: 8386517
Int J Pharm. 2010 Nov 15;400(1-2):234-42
pubmed: 20816730
Biomed Res Int. 2015;2015:790203
pubmed: 26583132
Ann Am Thorac Soc. 2016 Dec;13 Suppl 5:S417-S421
pubmed: 28005427
Biochem Biophys Res Commun. 2001 Feb 16;281(1):200-5
pubmed: 11178980
Biotechnol Bioeng. 2011 Aug;108(8):1977-86
pubmed: 21391205
Science. 1986 Aug 1;233(4763):532-4
pubmed: 3487831
Expert Rev Respir Med. 2018 May;12(5):375-385
pubmed: 29621919
J Pathol. 2008 Jan;214(2):199-210
pubmed: 18161745
Microbes Infect. 1999 Dec;1(15):1265-73
pubmed: 10611754
EMBO J. 2000 Apr 17;19(8):1745-54
pubmed: 10775259
Austin J Pulm Respir Med. 2014;1(1):3
pubmed: 25309962
J Cardiothorac Surg. 2013 Apr 16;8:90
pubmed: 23590942
Eur Respir Rev. 2015 Mar;24(135):102-14
pubmed: 25726561
Am J Physiol Lung Cell Mol Physiol. 2005 May;288(5):L841-8
pubmed: 15608148
J Exp Med. 2011 Jul 4;208(7):1459-71
pubmed: 21708929
Biochem J. 1987 Nov 1;247(3):597-604
pubmed: 3501287
Drug Des Devel Ther. 2015 Dec 14;9:6407-19
pubmed: 26715838
Mediators Inflamm. 2015;2015:764641
pubmed: 26199463
Am J Transl Res. 2016 May 15;8(5):1971-84
pubmed: 27347307
J Biomed Mater Res A. 2014 Jul;102(7):2173-80
pubmed: 23913854
PLoS One. 2010 Oct 07;5(10):e13242
pubmed: 20949050
Eur Respir Rev. 2012 Dec 1;21(126):355-61
pubmed: 23204124
Am J Pathol. 1996 Feb;148(2):527-37
pubmed: 8579115
Annu Rev Cell Dev Biol. 2007;23:435-61
pubmed: 17506690
J Control Release. 2015 May 28;206:131-9
pubmed: 25804871
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Front Pharmacol. 2014 May 27;5:123
pubmed: 24904424
Am Rev Respir Dis. 1989 Jul;140(1):95-100
pubmed: 2751176
Drug Des Devel Ther. 2012;6:261-72
pubmed: 23055696
Ann Rheum Dis. 2016 May;75(5):883-90
pubmed: 25858641
Thromb Res. 2014 Sep;134(3):639-42
pubmed: 25065557
Am J Physiol. 1997 Sep;273(3 Pt 1):L676-83
pubmed: 9316504
Am J Physiol Lung Cell Mol Physiol. 2000 May;278(5):L914-22
pubmed: 10781421
PLoS One. 2014 May 30;9(5):e98228
pubmed: 24878845
Eur Respir J. 2003 Jul;22(1):69-76
pubmed: 12882453
FASEB J. 2017 Mar;31(3):868-881
pubmed: 27903619
Thorax. 2006 Oct;61(10):886-94
pubmed: 16809410
Biomaterials. 2017 Nov;144:60-72
pubmed: 28823844
Autoimmun Rev. 2014 Apr-May;13(4-5):508-12
pubmed: 24424167
Eur Respir J. 2015 May;45(5):1434-45
pubmed: 25745043
Blood. 1997 Jun 1;89(11):4112-9
pubmed: 9166853
Am J Pathol. 1998 Feb;152(2):533-46
pubmed: 9466580
Am J Respir Cell Mol Biol. 2008 Sep;39(3):289-95
pubmed: 18390475
Dev Biol. 1993 Feb;155(2):324-36
pubmed: 8432391
J Invest Dermatol. 2008 Jul;128(7):1852-60
pubmed: 18200061

Auteurs

Elya A Shamskhou (EA)

Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA, 94305, USA.

Michael J Kratochvil (MJ)

Department of Materials Science and Engineering, Stanford University, Stanford, CA, 94305, USA; Department of Medicine, Division of Infectious Disease, Stanford University, Stanford, CA, 94305, USA.

Mark E Orcholski (ME)

Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA, 94305, USA.

Nadine Nagy (N)

Department of Medicine, Division of Infectious Disease, Stanford University, Stanford, CA, 94305, USA.

Gernot Kaber (G)

Department of Medicine, Division of Infectious Disease, Stanford University, Stanford, CA, 94305, USA.

Emily Steen (E)

Department of Surgery, Division of Pediatric Surgery, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, 77030, USA.

Swathi Balaji (S)

Department of Surgery, Division of Pediatric Surgery, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, 77030, USA.

Ke Yuan (K)

Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA, 94305, USA.

Sundeep Keswani (S)

Department of Surgery, Division of Pediatric Surgery, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, 77030, USA.

Ben Danielson (B)

Department of Medicine, Division of Infectious Disease, Stanford University, Stanford, CA, 94305, USA.

Max Gao (M)

Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA, 94305, USA.

Carlos Medina (C)

Department of Medicine, Division of Infectious Disease, Stanford University, Stanford, CA, 94305, USA.

Abinaya Nathan (A)

Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA, 94305, USA.

Ananya Chakraborty (A)

Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA, 94305, USA.

Paul L Bollyky (PL)

Department of Medicine, Division of Infectious Disease, Stanford University, Stanford, CA, 94305, USA.

Vinicio A De Jesus Perez (VA)

Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA, 94305, USA. Electronic address: vdejesus@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH